Theorem Clinical Research

AMRI

AMRI's expands discovery biology offerings

Monday, September 8, 2014 01:52 PM

Albany Molecular Research (AMRI), a New York-based global CRO, has expanded into the protein market, with an initial focus on protein expression and purification. The global revenue of the total proteomics market is anticipated to grow at a compound annual growth rate of about 4.1% to about $9.2 billion by 2018.

More... »


AMRI completes acquisition of Oso Biopharmaceuticals Manufacturing

Friday, July 4, 2014 10:00 PM

Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners.

More... »


AMRI to acquire OsoBio

Monday, June 2, 2014 01:13 PM

Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has signed a definitive agreement to acquire all outstanding membership interests of Oso Biopharmaceuticals Manufacturing (OsoBio) for $110 million in cash.

More... »

AMRI shutters New York research center, cuts 45 jobs

Friday, April 18, 2014 12:39 PM

Albany Molecular Research (AMRI), a global contract research and manufacturing organization, will be transitioning Discovery and Development Services (DDS) activities at its Syracuse, N.Y., site to other sites within AMRI and will cease operations in Syracuse by the end of June.

More... »

AMRI to acquire Cedarburg Pharmaceuticals

Monday, March 24, 2014 02:42 PM

Albany Molecular Research (AMRI), a global contract research and manufacturing organization based in Albany, N.Y., will acquire all outstanding shares of Cedarburg Pharmaceuticals for $38.2 million in cash. The transaction, including $2.8 million of assumed liabilities, is valued at $41 million.

More... »

AMRI Hires Vijay Kumar Batra as Managing Director, AMRI India

Wednesday, January 15, 2014 07:52 AM

Albany Molecular Research, a global contract research and manufacturing organization, has appointed Vijay Kumar Batra to managing director, AMRI India, effective Jan. 2. Batra will report to Steve Hagen, Ph.D., senior vice president of manufacturing and pharmaceuticals.

More... »

AMRI announces lifting of FDA warning letter

Wednesday, November 13, 2013 09:27 AM

Albany, N.Y.-based Albany Molecular Research (AMRI) has received a close-out letter from the FDA lifting a 2010 warning letter related to its Burlington, Mass., aseptic fill-and-finish facility.

More... »

AMRI awarded contract from U.K. government

Monday, October 7, 2013 03:22 PM

U.K.-based CRO Albany Molecular Research, a wholly owned subsidiary of AMRI, has been awarded a seven-year contract for the development and manufacture of an active ingredient under clinical evaluation. The contract was awarded by the Defense Science and Technology Laboratory, acting on behalf of the U.K.'s Secretary of State for Defense, the Department of National Defense of Canada and Minister of Defense of the Kingdom of the Netherlands.

More... »

AMRI announces executive leadership changes

Tuesday, September 10, 2013 10:01 AM

CRO Albany Molecular Research has announced Thomas E. D'Ambra, Ph.D., will retire as president and chief executive officer, effective Dec. 31. D'Ambra will be named non-executive chairman of the board of directors on the same date.

More... »

AMRI names business development director

Monday, June 17, 2013 02:00 PM

AMRI named Susan Collins director of business development for North American Discovery Services, reporting to Christopher Conway, vice president of business development. Collins is responsible for leading a team promoting AMRI's global drug discovery services.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs